AngioDynamics director receives 11,887-share stock grant

DONNELLY HOWARD W reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

DONNELLY HOWARD W reported acquisition or exercise transactions in this Form 4 filing.

AngioDynamics Inc director Howard W. Donnelly received a grant of 11,887 shares of common stock on July 15, 2026, representing 11,887 restricted stock units granted as regular annual compensation for board service. These units vested immediately, increasing his directly held common stock to 178,938 shares.

Insider Trade Summary

Grant/Award: 11,887 shares

Grant/Award 1 txn

Insider DONNELLY HOWARD W

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	11,887	$0.00	$0.00

Holdings After Transaction: Common Stock — 178,938 shares (Direct)

Footnotes (1)

1. F1. The acquisition of 11,887 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") represents 11,887 restricted stock units granted as regular annual compensation for service as a director of AngioDynamics. The restricted stock units immediately vested at the time of grant.

Key Figures

Shares granted: 11,887 shares Grant price per share: $0.00 Shares owned after grant: 178,938 shares

3 metrics

Shares granted 11,887 shares Restricted stock units granted as annual director compensation on July 15, 2026

Grant price per share $0.00 Reported transaction price per share for the stock grant

Shares owned after grant 178,938 shares Directly held AngioDynamics common stock following the reported award

Key Terms

restricted stock units, vested, regular annual compensation

3 terms

restricted stock units financial

"represents 11,887 restricted stock units granted as regular annual compensation"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

vested financial

"The restricted stock units immediately vested at the time of grant"

regular annual compensation financial

"restricted stock units granted as regular annual compensation for service as a director"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ANGO director Howard W. Donnelly report?

Howard W. Donnelly reported receiving 11,887 shares of AngioDynamics common stock as a grant. The award represents 11,887 restricted stock units for regular annual director compensation that vested immediately, bringing his direct holdings to 178,938 shares after the transaction.

Was the ANGO insider transaction a purchase or a compensation award?

The ANGO transaction was a compensation award, not an open-market purchase. Donnelly received 11,887 restricted stock units as regular annual director compensation, which converted into common stock at a reported price of $0.00 per share and vested immediately.

How many AngioDynamics (ANGO) shares does Howard W. Donnelly own after this grant?

Following the July 15, 2026 award, Howard W. Donnelly directly owns 178,938 shares of AngioDynamics common stock. This total includes the 11,887 shares underlying restricted stock units granted as part of his regular annual compensation for serving as a director.

What are the key details and date of the latest ANGO director equity grant?

On July 15, 2026, AngioDynamics granted director Howard W. Donnelly 11,887 restricted stock units as regular annual compensation. The units immediately vested upon grant, resulting in direct ownership of 178,938 common shares after the transaction was recorded.

Did the ANGO director’s restricted stock units vest immediately?

Yes. The filing states the 11,887 restricted stock units granted to Howard W. Donnelly as annual director compensation immediately vested at the time of grant, meaning they converted into common shares without a waiting or vesting period.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/22/2026 - 08:06 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DONNELLY HOWARD W

(Last) (First) (Middle)

14 PLAZA DRIVE

(Street)

LATHAM NEW YORK 12110

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ANGIODYNAMICS INC [ ANGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/15/2026		A		11,887(1)	A	$0	178,938	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The acquisition of 11,887 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") represents 11,887 restricted stock units granted as regular annual compensation for service as a director of AngioDynamics. The restricted stock units immediately vested at the time of grant.

	/s/ Lawrence T. Weiss, Attorney in Fact	07/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)